Printer Friendly

RHONE-POULENC RORER APPOINTS NEW PRESIDENT OF RESEARCH AND DEVELOPMENT

RHONE-POULENC RORER APPOINTS NEW PRESIDENT OF RESEARCH AND DEVELOPMENT
 COLLEGEVILLE, Pa., April 1 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR), a global pharmaceutical company, announced today the appointment of Manfred Karobath, M.D., as senior vice president, RPR, and president, RPR Research and Development.
 In this position, Karobath will be responsible for worldwide research and development operations, based in Paris.
 Karobath joins RPR from Sandoz Pharma Ltd. in Basle, Switzerland, where he was senior vice president, Research and Development, responsible for discovery research, pharmaceutical development and clinical research there. Prior to this position, he was responsible for all pharmaceutical research at Sandoz Pharma in Switzerland and, prior to that, for pre-clinical central nervous system research and pre-clinical research in geriatrics.
 Karobath obtained his M.D. from the University of Vienna and was a post-doctoral fellow at Vienna University and Harvard University Medical School.
 "Throughout his distinguished career, Dr. Karobath has fostered the values of scientific excellence, quality and a strong sense of urgency in bringing life-saving and life-enhancing products to market," said Robert E. Cawthorn, chairman and chief executive officer, RPR. "He is a valuable addition to the RPR management team."
 In this position, Karobath succeeds James R. Tretter, Ph.D., who had previously announced his intention to retire from RPR in mid-1992.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. In 1991, the company had sales of $3.8 billion, and it plans to invest approximately $500 million in research and development in 1992.
 RPR has approximately 3,400 people in its research and development organization worldwide, and has major research and development facilities in Paris; Collegeville; and Dagenham, England. The company focuses on the following therapeutic areas: cardiovascular medicine, infectious diseases and AIDS, central nervous system disorders and pain, respiratory diseases, bone metabolism disorders and rheumatology, and cancer; the company also develops and markets plasma derivatives, over-the-counter pharmaceuticals, and dermatologicals.
 /delval/
 -0- 4/1/92
 /CONTACT: Rhone-Poulenc Rorer media relations, 215-454-3871, or investor relations, 215-454-3851/ CO: Rhone-Poulenc Rorer Inc. ST: Pennsylvania IN: MTC SU: PER


CC -- PH003 -- 3743 04/01/92 09:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1992
Words:355
Previous Article:CLOTHESTIME TO OPEN FOLSOM STORE
Next Article:TEXTRON TO REDEEM ITS 11-3/4 PERCENT SUBORDINATED NOTES DUE 1995
Topics:


Related Articles
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMIT $18 MILLION ADDITIONAL FUNDING FOR AIDS JOINT VENTURE
ARMOUR PHARMACEUTICAL COMPANY APPOINTS TWO NEW EXECUTIVES
RHONE-POULENC ANNOUNCES ORGANIZATIONAL APPOINTMENTS
Rossella Daverio Named Senior Vice-President, Communications of Rhone-Poulenc Rorer Inc.
ESMO/Rhone-Poulenc Rorer Fellowship Awarded To Adam Pawinski, M.D.
RPR Implements New Management Structure in Japan
RPR Announces New Head of Research
Marie-Dominique de La Salle Named Vice President, Communications, Of Rhone-Poulenc Rorer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters